Free Trial
NASDAQ:TSBX

Turnstone Biologics Q1 2025 Earnings Report

Turnstone Biologics logo
$0.36 +0.01 (+3.05%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.28%)
As of 06/6/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.26
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

Turnstone Biologics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Turnstone Biologics Earnings Headlines

BofA: Is this the next SpaceX?
Everyone is focusing on AI stocks... Yet little-known "space stocks" are rocketing to record highs with gains of 588% - 3,710%! One new space stock that I call "the next SpaceX" is preparing to IPO on the NASDAQ. Right now, you can grab Pre-IPO shares for less than $4.00. And my estimates suggest the valuation could soar 457% with the IPO. Get urgent details inside this free report...
Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat